{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:51:27Z","timestamp":1762642287968,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["ASPIRE #WI195021"],"award-info":[{"award-number":["ASPIRE #WI195021"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s10067-019-04874-x","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T22:02:32Z","timestamp":1576706552000},"page":"787-794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer"],"prefix":"10.1007","volume":"39","author":[{"given":"Xerxes","family":"Pundole","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia V.","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harish","family":"Siddhanamatha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Tayar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leung Cheuk","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,18]]},"reference":[{"key":"4874_CR1","doi-asserted-by":"publisher","unstructured":"Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dorner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Rubbert-Roth A, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop KL (2013) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 72 Suppl 2:ii2-34. doi:https:\/\/doi.org\/10.1136\/annrheumdis-2013-203348","DOI":"10.1136\/annrheumdis-2013-203348"},{"key":"4874_CR2","unstructured":"Amjevita [package insert]. Thousand Oaks, CA: Amgen; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761024s004lbl.pdf. Accessed 30 Sept 2019"},{"key":"4874_CR3","unstructured":"Inflectra [package insert]. Republic of Korea: Celltrion, Inc; 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761024s004lbl.pdf. Accessed 30 Sept 2019"},{"issue":"1","key":"4874_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","volume":"137","author":"M Her","year":"2016","unstructured":"Her M, Kavanaugh A (2016) Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol 137(1):19\u201327. https:\/\/doi.org\/10.1016\/j.jaci.2015.10.023","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"4874_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/BOR.0000000000000072","volume":"26","author":"D Wallis","year":"2014","unstructured":"Wallis D (2014) Infection risk and biologics: current update. Curr Opin Rheumatol 26(4):404\u2013409. https:\/\/doi.org\/10.1097\/BOR.0000000000000072","journal-title":"Curr Opin Rheumatol"},{"issue":"19","key":"4874_CR6","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275\u20132285. https:\/\/doi.org\/10.1001\/jama.295.19.2275","journal-title":"JAMA"},{"issue":"2","key":"4874_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/pds.2046","volume":"20","author":"J Askling","year":"2011","unstructured":"Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D (2011) Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 20(2):119\u2013130. https:\/\/doi.org\/10.1002\/pds.2046","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"4874_CR8","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1136\/ard.2008.091025","volume":"68","author":"JP Leombruno","year":"2009","unstructured":"Leombruno JP, Einarson TR, Keystone EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68(7):1136\u20131145. https:\/\/doi.org\/10.1136\/ard.2008.091025","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4874_CR9","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/art.30310","volume":"63","author":"AE Thompson","year":"2011","unstructured":"Thompson AE, Rieder SW, Pope JE (2011) Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 63(6):1479\u20131485. https:\/\/doi.org\/10.1002\/art.30310","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4874_CR10","doi-asserted-by":"publisher","first-page":"e6055","DOI":"10.1097\/MD.0000000000006055","volume":"96","author":"JL Lan","year":"2017","unstructured":"Lan JL, Tseng CH, Chen JH, Cheng CF, Liang WM, Tsay GJ (2017) Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-alpha inhibitor. Medicine (Baltimore) 96(7):e6055. https:\/\/doi.org\/10.1097\/MD.0000000000006055","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"4874_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s13075-014-0449-5","volume":"16","author":"CY Wu","year":"2014","unstructured":"Wu CY, Chen DY, Shen JL, Ho HJ, Chen CC, Kuo KN, Liu HN, Chang YT, Chen YJ (2014) The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study. Arthritis Res Ther 16(5):449. https:\/\/doi.org\/10.1186\/s13075-014-0449-5","journal-title":"Arthritis Res Ther"},{"key":"4874_CR12","doi-asserted-by":"publisher","unstructured":"Lopez-Olivo MA, Colmegna I, Karpes AR, Qi SR, Zamora NV, Sharma R, Pratt G, Suarez-Almazor ME (2019) Systematic review of recommendations on the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and cancer. Arthritis Care Res. https:\/\/doi.org\/10.1002\/acr.23865","DOI":"10.1002\/acr.23865"},{"issue":"6","key":"4874_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/acr.20129","volume":"62","author":"WG Dixon","year":"2010","unstructured":"Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP, British Society For Rheumatology Biologics Register Control Centre C, British Society for Rheumatology Biologics R (2010) Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res 62(6):755\u2013763. https:\/\/doi.org\/10.1002\/acr.20129","journal-title":"Arthritis Care Res"},{"issue":"11","key":"4874_CR14","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1093\/rheumatology\/kew314","volume":"55","author":"L Silva-Fernandez","year":"2016","unstructured":"Silva-Fernandez L, Lunt M, Kearsley-Fleet L, Watson KD, Dixon WG, Symmons DP, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre C (2016) The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology (Oxford) 55(11):2033\u20132039. https:\/\/doi.org\/10.1093\/rheumatology\/kew314","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"4874_CR15","doi-asserted-by":"publisher","first-page":"R5","DOI":"10.1186\/ar2904","volume":"12","author":"A Strangfeld","year":"2010","unstructured":"Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, Listing J, Zink A (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12(1):R5. https:\/\/doi.org\/10.1186\/ar2904","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"4874_CR16","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1136\/annrheumdis-2014-205745","volume":"74","author":"P Raaschou","year":"2015","unstructured":"Raaschou P, Frisell T, Askling J, Group AS (2015) TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 74(12):2137\u20132143. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205745","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4874_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.7326\/M17-2812","volume":"169","author":"P Raaschou","year":"2018","unstructured":"Raaschou P, Soderling J, Turesson C, Askling J, Group AS (2018) Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: a nationwide population-based cohort study. Ann Intern Med 169(5):291\u2013299. https:\/\/doi.org\/10.7326\/M17-2812","journal-title":"Ann Intern Med"},{"key":"4874_CR18","doi-asserted-by":"publisher","unstructured":"Xie W, Xiao S, Huang Y, Sun X, Gao D, Ji L, Li G, Zhang Z (2019) A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/kez475","DOI":"10.1093\/rheumatology\/kez475"},{"issue":"4","key":"4874_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343\u2013346","journal-title":"Control Clin Trials"},{"issue":"Suppl 1","key":"4874_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2147\/CLEP.S47150","volume":"5","author":"M S\u00f8gaard","year":"2013","unstructured":"S\u00f8gaard M, Thomsen RW, Bossen KS, S\u00f8rensen HT, N\u00f8rgaard M (2013) The impact of comorbidity on cancer survival: a review. Clin Epidemiol 5(Suppl 1):3\u201329","journal-title":"Clin Epidemiol"},{"issue":"1","key":"4874_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MLR.0b013e318180913c","volume":"47","author":"TP Ahern","year":"2009","unstructured":"Ahern TP, Lash TL, Thwin SS, Silliman RA (2009) Impact of acquired comorbidities on all-cause mortality rates among older breast cancer survivors. Med Care 47(1):73\u201379","journal-title":"Med Care"},{"issue":"4","key":"4874_CR22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.oraloncology.2004.08.012","volume":"41","author":"PA Borggreven","year":"2005","unstructured":"Borggreven PA, Kuik DJ, Langendijk JA, Doornaert P, de Bree R, Leemans CR (2005) Severe comorbidity negatively influences prognosis in patients with oral and oropharyngeal cancer after surgical treatment with microvascular reconstruction. Oral Oncol 41(4):358\u2013364","journal-title":"Oral Oncol"},{"issue":"7","key":"4874_CR23","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/1055-9965.Epi-11-1228","volume":"21","author":"D Braithwaite","year":"2012","unstructured":"Braithwaite D, Moore DH, Satariano WA, Kwan ML, Hiatt RA, Kroenke C, Caan BJ (2012) Prognostic impact of comorbidity among long-term breast cancer survivors: results from the LACE study. Cancer Epidem Biomar 21(7):1115\u20131125. https:\/\/doi.org\/10.1158\/1055-9965.Epi-11-1228","journal-title":"Cancer Epidem Biomar"},{"issue":"5","key":"4874_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11606-011-1869-4","volume":"27","author":"K Chamie","year":"2012","unstructured":"Chamie K, Daskivich TJ, Kwan L, Labo J, Dash A, Greenfield S, Litwin MS (2012) Comorbidities, treatment and ensuing survival in men with prostate cancer. J Gen Intern Med 27(5):492\u2013499","journal-title":"J Gen Intern Med"},{"issue":"10","key":"4874_CR25","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/sj.bjc.6602836","volume":"93","author":"B Colinet","year":"2005","unstructured":"Colinet B, Jacot W, Bertrand D, Lacombe S, Bozonnat M, Daures J, Pujol J (2005) A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson\u2019s index. Br J Cancer 93(10):1098\u20131105","journal-title":"Br J Cancer"},{"issue":"1","key":"4874_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0959-8049(99)00221-X","volume":"36","author":"M De Marco","year":"2000","unstructured":"De Marco M, Janssen-Heijnen M, Van der Heijden L, Coebergh J (2000) Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer 36(1):95\u201399","journal-title":"Eur J Cancer"},{"issue":"2","key":"4874_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.7326\/0003-4819-120-2-199401150-00002","volume":"120","author":"WA Satariano","year":"1994","unstructured":"Satariano WA, Ragland DR (1994) The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120(2):104\u2013110","journal-title":"Ann Intern Med"},{"issue":"11","key":"4874_CR28","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2123::AID-CNCR6>3.0.CO;2-W","volume":"82","author":"R Yancik","year":"1998","unstructured":"Yancik R, Wesley MN, Ries LA, Havlik RJ, Long S, Edwards BK, Yates JW (1998) Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients. Cancer 82(11):2123\u20132134","journal-title":"Cancer"},{"issue":"9","key":"4874_CR29","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/2012.jama.10857","volume":"308","author":"MA Lopez-Olivo","year":"2012","unstructured":"Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, Fulton S, Suarez-Almazor ME (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308(9):898\u2013908. https:\/\/doi.org\/10.1001\/2012.jama.10857","journal-title":"JAMA"},{"issue":"6","key":"4874_CR30","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","volume":"76","author":"S Ramiro","year":"2017","unstructured":"Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Bijlsma JW, Burmester GR (2017) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 76(6):1101\u20131136","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4874_CR31","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","volume":"76","author":"LK Mercer","year":"2017","unstructured":"Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, Strangfeld A, Zink A, Mariette X, Finckh A, Canhao H, Lannone F, Zavada J, Morel J, Gottenberg JE, Hyrich KL, Listing J (2017) Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis 76(2):386\u2013391. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209285","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4874_CR32","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3899\/jrheum.140853","volume":"42","author":"KJ Aaltonen","year":"2015","unstructured":"Aaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, Valleala H, Rantalaiho V, Piril\u00e4 L, Puolakka K (2015) Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol 42(3):372\u2013378","journal-title":"J Rheumatol"},{"issue":"4","key":"4874_CR33","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/art.40017","volume":"69","author":"K Hellgren","year":"2017","unstructured":"Hellgren K, Baecklund E, Backlin C, Sundstrom C, Smedby K, Askling J (2017) Rheumatoid arthritis and risk of malignant lymphoma: is the risk still increased? Arthritis Rheum 69(4):700\u2013708","journal-title":"Arthritis Rheum"},{"issue":"9","key":"4874_CR34","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1002\/art.22056","volume":"54","author":"S Setoguchi","year":"2006","unstructured":"Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S (2006) Tumor necrosis factor \u03b1 antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54(9):2757\u20132764","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4874_CR35","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum 68(1):1\u201326","journal-title":"Arthritis Rheum"},{"key":"4874_CR36","doi-asserted-by":"publisher","first-page":"S342","DOI":"10.1002\/art.37749","volume":"65","author":"A Strangfeld","year":"2013","unstructured":"Strangfeld A, Pattloch D, Herzer P, Edelmann E, Zinke S, Aringer M, Listing J, Zink A (2013) Risk of cancer recurrence or new tumors in RA patients with prior malignancies treated with various biologic agents. Arthritis Rheum-Us 65:S342\u2013S342","journal-title":"Arthritis Rheum-Us"},{"issue":"7","key":"4874_CR37","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/art.30247","volume":"63","author":"P Raaschou","year":"2011","unstructured":"Raaschou P, Simard JF, Neovius M, Askling J, Group ARTiSS (2011) Does cancer that occurs during or after anti\u2013tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum 63(7):1812\u20131822","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04874-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04874-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04874-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:42:07Z","timestamp":1608165727000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04874-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,18]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["4874"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04874-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2019,12,18]]},"assertion":[{"value":"12 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional review board approval was obtained before any data were collected for this study. The use of patient information complied with the Health Insurance Portability and Accountability Act, and sensitive patient data were protected in the data analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Xerxes Pundole\u2014noneNatalia V. Zamora\u2014noneHarish Siddhanamatha\u2014noneHeather Lin\u2014noneJean Tayar\u2014noneLeung Cheuk Hong\u2014noneLiang Li\u2014noneMaria E. Suarez-Almazor \u2013 Dr. Suarez-Almazor has been a consultant for Pfizer, AbbVie and Agile Pharmaceuticals","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}